Arthneeti

Divis Laboratories Q1 FY27 Share Price & Earnings Call Analysis

₹9,664.00+1.10% today
Market cap
₹2.57L Cr
P/E
86.11
ROE
16.53%
PEG
6.69
Price to sales
22.85
Debt to equity
0.00
52W high / low
₹9,664 / ₹5,821
Sales growth (5Y)
8.67%
EBITDA margin
35.33%
Net profit margin
24.84%
Promoter holding
51.87%
Sales (last year)
₹11,230 Cr

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

Guidance scorecard · Q1 FY27 call

What Divi's Lab.'s management guided
and where it ranks in Pharmaceuticals & Biotechnology

#52of 83 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • The company targets double-digit growth in revenue and sales consistently, as stated by both Dr. Kiran S. Divi and Nilima Prasad Divi.
  • Growth is driven by ongoing validation and commercialization of new projects, including peptides and small molecules.
  • Several validation batches are continuing, with multiple projects in different development stages expected to contribute revenue gradually.
  • The launch of commercial volumes post-regulatory approvals will positively impact growth, though timelines depend on approvals.
  • Expansion projects (capex of around ₹2,000 crores, 70% incurred) will support capacity additions and future growth.
  • Growth assumes a healthy product mix without over-reliance on any single product or customer.

2 more points from Divi's Lab.'s call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Divi's Lab. said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Divi’s Laboratories has three major ongoing capex projects nearing completion, with about 70% of the ₹2,000 crores investment capitalized so far.
  • These projects include capacity expansions supporting validation batches and future commercial production, with one related long-term contract negotiation in the contrast media segment.
  • Significant capacity expansions are underway in peptide manufacturing, including installing multiple 3,000-liter solid-phase peptide synthesis (SPPS) lines to capture future opportunities.
  • Unit 3 plays a strategic role by supporting backward integration, pre-chemistry operations, and enabling efficient capacity utilization through phased manufacturing transfers.

2 more points from Divi's Lab.'s call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Divi's Lab. said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • Divi's Laboratories is currently engaged in validation batches for several projects, including three major dedicated capex projects involving different products.
  • Due to confidentiality and CDAs, specific details on order book size, product names, or quantities cannot be disclosed.
  • The company has supplied validation quantities for about 4 new DMFs as part of their generic portfolio, which are undergoing customer qualification.
  • Several projects are in various pipeline stages: clinical studies, pre-validation, and validations.
  • Commercial supplies will only start after customer qualifications and regulatory approvals.
  • The firm expects a double-digit growth in revenue, supported by ongoing and upcoming validations leading to commercial orders.

2 more points from Divi's Lab.'s call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Divi's Lab. rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Divi's Lab..

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Divi's Lab.

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Divi's Lab.

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +1,9511,7781,9091,8552,3032,1182,3382,3192,5852,4102,7152,6042,831
Expenses +1,4641,2741,4301,3661,5721,4961,6221,5761,6991,6811,8271,7141,897
Operating Profit487504479489731622716743886729888890934
OPM %25%28%25%26%32%29%31%32%34%30%33%34%33%
Other Income +668186957979106828611914514155
Interest0010201013866
Depreciation8793959595979999107112113118120
Profit before tax466492469489713604722726864733912780963
Tax %31%28%26%27%25%29%29%19%23%26%24%25%22%
Net Profit +321356348358538430510589662545689583751
EPS in Rs12.0913.4113.1113.4920.2716.2019.2122.1924.9420.5325.9521.9628.29

Financials of Divi's Lab.

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +3,1153,7764,0643,8914,9465,3946,9698,9607,7687,8459,36010,560
Expenses +1,9422,3542,6152,6223,0723,5684,1025,0755,3975,6356,3877,119
Operating Profit1,1731,4231,4501,2691,8741,8262,8673,8852,3702,2102,9733,441
OPM %38%38%36%33%38%34%41%43%31%28%32%33%
Other Income +38937210715418657112344335348433
Interest3532572224323
Depreciation136118123142169186256312343378402463
Profit before tax1,0721,3931,3951,2311,8551,8192,6663,6842,3692,1632,9163,388
Tax %21%19%24%29%27%24%26%20%23%26%25%24%
Net Profit +8521,1261,0608771,3531,3771,9842,9601,8231,6002,1912,568
EPS in Rs32.0742.4139.9533.0450.9651.8574.75111.5268.6960.2782.5396.73
Dividend Payout %31%24%25%30%31%31%27%27%44%50%36%31%

Financials of Divi's Lab.

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital275353535353535353535353
Reserves3,4694,2405,3045,8726,9047,2579,24211,67512,71413,51814,91616,708
Borrowings +2742366310639543347
Other Liabilities +8835627627979731,1831,4711,6281,6541,8861,9483,265
Total Liabilities4,4054,8986,1556,7858,0368,53110,77113,36014,42515,46016,92120,033
Fixed Assets +1,3091,4391,5591,9962,0882,7823,7044,3254,7234,7395,4426,528
CWIP2182644441204929207114702127781,0222,113
Investments7338031,6311,8891,94697107277826569
Other Assets +2,1452,3922,5212,7803,5113,8586,3568,4939,4139,86110,39211,323
Total Assets4,4054,8986,1556,7858,0368,53110,77113,36014,42515,46016,92120,033

Financials of Divi's Lab.

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +8261,0381,1507769541,2161,9471,9122,4601,2611,6532,738
Cash from Investing Activity +-521-406-1,140-478-685-8375-2,195-2,708-269-804-2,219
Cash from Financing Activity +-303-6312-314-246-1,091-35-532-797-799-799-804
Net Cash Flow3013-1723411,987-816-1,04519350-285
Free Cash Flow519642774502221331,0371,1991,987258215221
CFO/OP88%91%100%82%77%91%90%66%124%74%83%105%

Financials of Divi's Lab.

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days878581958696889984100106103
Inventory Days350293307314347316329341352364311353
Days Payable6856104969610011796899488108
Cash Conversion Cycle368322284313336312300344347370330348
Working Capital Days140158147176169180152177188206192195
ROCE %33%36%29%22%29%25%32%35%19%16%20%22%

Guidance history

How Divi's Lab.'s guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlanned——
Q4 FY26 call →10–20%FlatPlanned——
Q3 FY26 call →10–20%FlatPlanned—Rising
Q2 FY26 call →10–20%FlatPlanned—Rising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

87out of 100

Momentum score · price trend

87 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+48.4%84%
Last 6 months+48.6%89%
Last 3 months+23.3%88%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Divi's Lab.: 0.4 × 84 + 0.4 × 89 + 0.2 × 88 = 87.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Divi's Lab.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Torrent Pharmaceuticals Ltdvs Laurus Labs Ltd